Back

Clinical profile, treatment selection, and early outcomes with TTR stabilizers to treat patients with transthyretin cardiac amyloidosis: a real-world study

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy (4) Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Rui Miguel Esculudes Dos Santos Ferrao Gomes

Centro Universitario da Unidade Local de Saude de Lisboa Ocidental, Lisboa (Portugal)

5 More presentations in this session

Presentation thumbnail
Clinical predictors of all-cause mortality and heart failure readmissions after intermittent levosimendan
Doctor R. Brandao (Amadora, PT)
Abstract
Presentation thumbnail
Tafamidis non-responders in cardiac amyloidosis: clinical characterization of a real-world cohort
Doctor I. Cruz (Coimbra, PT)
Abstract
Presentation thumbnail
Effect of intravenous repletion of ferric hydroxide sucrose on the functional capacity of pacients with heart failure
Mrs A. Freitas (Curitiba, BR)
Abstract
Presentation thumbnail
One-year maintenance of SGLT2 inhibitor therapy in octogenarians following acute heart failure with preserved or mildly reduced ejection fraction
Mrs S. Valdivielso (Barcelona, ES)
Abstract
Presentation thumbnail
Predicted natriuretic output and cardiorenal phenotyping in hospitalised heart failure
Doctor S. Singh (Hartford, US)
Abstract

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy (4)

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Presentation
Audience Q&A
thumbnail
Congress Presentation
Treating heart failure in adult congenital heart disease: A-Z

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources